In recent days, UiPath has drawn fresh attention as easing geopolitical tensions and a friendlier backdrop for technology spending have supported renewed interest in AI automation platforms, including its Maestro orchestration offering for AI agents, software bots, and humans.
At the same time, UiPath’s agentic AI capabilities, highlighted by benchmark-leading Screen Agent performance and growing analyst focus on its automation platform, have sharpened the debate over whether its technical strengths can translate into sustained commercial traction.
We’ll now examine how UiPath’s push into agentic AI orchestration shapes its investment narrative and what the recent news means for investors.
AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.
To stay invested in UiPath, you need to believe that its RPA roots can evolve into a broad agentic AI orchestration platform where Maestro, Screen Agent and a growing partner ecosystem become core infrastructure for enterprise automation. The recent pop on easing geopolitical tensions and renewed interest in AI stocks is more sentiment than substance, and does little to change the near term story: execution on agentic AI use cases, proof that benchmark wins can support UiPath’s revenue guidance, and disciplined capital deployment after sizeable buybacks and new tuck in M&A ambitions. The bigger swing factors remain earnings quality, how quickly customers adopt cross vendor AI orchestration, and whether insider selling and share price volatility keep weighing on the multiple despite profitability and a modest discount to analyst fair value.
However, recent insider selling and volatile sentiment are key risks current and prospective investors should understand. UiPath’s shares have been on the rise but are still potentially undervalued by 17%. Find out what it’s worth.
PATH 1-Year Stock Price Chart
Ten fair value estimates from the Simply Wall St Community span roughly US$13.87 to just over US$21.50, showing wide disagreement. Set this against the current focus on agentic AI execution and volatility risk, and you can see why it helps to weigh several viewpoints before forming your own view on UiPath’s prospects.
Explore 10 other fair value estimates on UiPath – why the stock might be worth as much as 46% more than the current price!
Disagree with this assessment? Create your own narrative in under 3 minutes – extraordinary investment returns rarely come from following the herd.
Markets shift fast. These stocks won’t stay hidden for long. Get the list while it matters:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PATH.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com